JP2024526820A5 - - Google Patents

Info

Publication number
JP2024526820A5
JP2024526820A5 JP2024502611A JP2024502611A JP2024526820A5 JP 2024526820 A5 JP2024526820 A5 JP 2024526820A5 JP 2024502611 A JP2024502611 A JP 2024502611A JP 2024502611 A JP2024502611 A JP 2024502611A JP 2024526820 A5 JP2024526820 A5 JP 2024526820A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
fusion protein
composition according
actrii
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024502611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526820A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/037479 external-priority patent/WO2023003815A1/en
Publication of JP2024526820A publication Critical patent/JP2024526820A/ja
Publication of JP2024526820A5 publication Critical patent/JP2024526820A5/ja
Pending legal-status Critical Current

Links

JP2024502611A 2021-07-19 2022-07-18 Actriiタンパク質およびその用途 Pending JP2024526820A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163223265P 2021-07-19 2021-07-19
US63/223,265 2021-07-19
PCT/US2022/037479 WO2023003815A1 (en) 2021-07-19 2022-07-18 Actrii proteins and uses thereof

Publications (2)

Publication Number Publication Date
JP2024526820A JP2024526820A (ja) 2024-07-19
JP2024526820A5 true JP2024526820A5 (cg-RX-API-DMAC7.html) 2025-07-17

Family

ID=84979535

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502611A Pending JP2024526820A (ja) 2021-07-19 2022-07-18 Actriiタンパク質およびその用途

Country Status (18)

Country Link
US (1) US20240327494A1 (cg-RX-API-DMAC7.html)
EP (1) EP4373577A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024526820A (cg-RX-API-DMAC7.html)
KR (1) KR20240049857A (cg-RX-API-DMAC7.html)
CN (1) CN117957014A (cg-RX-API-DMAC7.html)
AU (1) AU2022316103A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225613A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000151A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024001551A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240061A (cg-RX-API-DMAC7.html)
DO (2) DOP2024000016A (cg-RX-API-DMAC7.html)
EC (1) ECSP24012819A (cg-RX-API-DMAC7.html)
GE (1) GEP20267899B (cg-RX-API-DMAC7.html)
IL (1) IL310141A (cg-RX-API-DMAC7.html)
JO (1) JOP20240010A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024000829A (cg-RX-API-DMAC7.html)
PE (1) PE20240777A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023003815A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4121078A4 (en) 2020-03-20 2024-08-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI745271B (zh) * 2014-05-19 2021-11-11 美商西建公司 全身紅斑性狼瘡之治療
WO2016146573A1 (en) * 2015-03-13 2016-09-22 Repoceuticals Aps Melatonin for preventing and treating radiation cystitis
JP7072507B2 (ja) * 2015-11-23 2022-05-20 アクセルロン ファーマ インコーポレイテッド 眼の障害を処置するための方法
PL4218804T3 (pl) * 2016-06-13 2026-05-25 Scholar Rock, Inc. Stosowanie inhibitorów miostatyny i terapii skojarzonych
AU2017296040C1 (en) * 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension

Similar Documents

Publication Publication Date Title
JP2009536201A5 (cg-RX-API-DMAC7.html)
JP2010518079A5 (cg-RX-API-DMAC7.html)
JP2017538395A5 (cg-RX-API-DMAC7.html)
JP2020063261A (ja) TNFR及びFc領域を含む融合タンパク質の液体製剤
JPH04500068A (ja) 敗血症性ショックの治療および予防のための方法および組成物
JP2016534052A5 (cg-RX-API-DMAC7.html)
JP2023040169A5 (cg-RX-API-DMAC7.html)
JP2016536369A5 (cg-RX-API-DMAC7.html)
JP2023545707A5 (cg-RX-API-DMAC7.html)
RU2007119989A (ru) Композиции, слитые конструкции и конъюгаты plad домена
JP2018501201A5 (cg-RX-API-DMAC7.html)
JP2021514354A5 (cg-RX-API-DMAC7.html)
US5660826A (en) Therapeutic sepsis treatment using antagonists to PTHrP
JP2024525795A5 (cg-RX-API-DMAC7.html)
JP2025518227A (ja) mazdutideを使用する治療方法
WO2015055026A1 (zh) 重组灵芝免疫调节蛋白与人血清白蛋白融合蛋白及其制备方法与应用
CN112390884B (zh) Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用
JP2024546129A5 (cg-RX-API-DMAC7.html)
FI114011B (fi) Suonensisäiseen käyttöön tarkoitetun immunoglobuliinin käyttö farmaseuttisen koostumuksen valmistamiseksi syöpäsairauksien hoitamiseksi
JP2002522512A (ja) デキストラン−レプチン結合体、医薬組成物および関連方法
JPH11512747A (ja) 造血幹細胞の動員方法
JP2024519904A5 (cg-RX-API-DMAC7.html)
JP2023537115A5 (cg-RX-API-DMAC7.html)
AU2007207074B2 (en) Isolated organ perfusion combination therapy of cancer
JP2025509520A5 (cg-RX-API-DMAC7.html)